Navigation Links
Golden Meditech Pioneers into China's Hospital Market
Date:6/24/2008

l cord blood stem cell transplantation, mismatched haploidentical transplantation, syngenic (twins) transplantation and autologous transplantation. During the past six years, Daopei Hospitals conducted about 690 cases of allergenic cord blood stem cell transplantation with successful implantation rate of 99.67% and overall survival rate of 70%, reaching an international level. The hospitals' reputation attracts numerous domestic and overseas leukaemia patients every year, and currently, their utilization rates of hospital beds exceed 100%.

Mr. LU Dao Pei, founder of the Daopei Hospitals, is a renowned haematologist and the so-called "Father of Bone Marrow Transplant "in China, an elected member of the Chinese Academy of Engineering (Division of Medicine and Health), a committee member of the Academic Committee of Peking University Health Science Center, and the Chief Expert for Haematology, National Key Disciplines in Peking University.

The Beijing and Shanghai Daopei Hospital are few privately-run hospitals, covered by the country's basic medical insurance scheme. In addition, Daopei Hospitals are also the only private specialist hospital endorsed to perform blood stem cell transplants.

Golden Meditech: Founded in 2000 and listed on the Growth Enterprise Market of the Stock Exchange of Hong Kong Limited in December 2001, Golden Meditech is the first hi-tech medical device enterprise that went public outside of the PRC. During the past few years, thanks to its great efforts in innovation and market expansion, as well as its first-mover abilities in capturing the emerging market opportunities, Golden Meditech's medical device, cord blood banking services and natural herbal medicine have all established dominant positions in each of the segments that the company engages in. Going forward, Golden Meditech will continue its pursuit of becoming China's leading integrated medical group through organic growth, acquisition and strategic investment.


'/>"/>
SOURCE Golden Meditech Company Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Golden Corrals Good Health Recipe for the Flu Season
2. National Energy Services Receives Repeat Orders From Golden Living and Cathedral Rock Skilled Nursing Facilities
3. Giving Back to the Community Golden Corral Style
4. Golden Doctor of Chiropractic Elected President of the Colorado Chiropractic Association
5. Kaiser Permanente and Golden State Warriors Team Up to Fight Childhood Obesity
6. Histochemistry is the golden standard in the diagnosis of carcinosarcomas
7. Emmy(R)- and Golden Globe(R)-Nominated Actress Marcia Cross and Lifetime Television Deliver 20 Million Online Petition Signatures to Capitol Hill to Urge Congress to Stop Drive-Through Mastectomies
8. Author Elizabeth Golden and Dancer Sarah Patellos to Serve as National Spokespersons for the National Scoliosis Foundation
9. American Airlines Honors Flight Attendants at Golden Heart Awards Ceremony
10. Golden State Medical Supply Selects IBM Technology to Comply With California Prescription Drug Pedigree Regulations
11. Golden Rainbow Takes a Musical Journey for Its 22nd Annual Ribbon of Life Production Show
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:Union Hospital, Hong Kong, Selects First DataBank's Electronic Drug Information in Medication Safety Initiative 2Health News:Union Hospital, Hong Kong, Selects First DataBank's Electronic Drug Information in Medication Safety Initiative 3Health News:Wellness Manufacturer Wins Two 2009 American Spa Awards 2Health News:Obesity and Inactivity -- The Biggest Threat to the Nation's Health 2Health News:Obesity and Inactivity -- The Biggest Threat to the Nation's Health 3Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 2Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 3Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 4Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 5Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 6Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 7Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 8Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 9Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 10Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 11Health News:Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765 2Health News:Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765 3Health News:Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765 4Health News:Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765 5
Breaking Medicine Technology:$232 Billion Personalized Medicine Market to Grow 11 Percent Annually, says PricewaterhouseCoopers 2$232 Billion Personalized Medicine Market to Grow 11 Percent Annually, says PricewaterhouseCoopers 3$232 Billion Personalized Medicine Market to Grow 11 Percent Annually, says PricewaterhouseCoopers 4$232 Billion Personalized Medicine Market to Grow 11 Percent Annually, says PricewaterhouseCoopers 5$232 Billion Personalized Medicine Market to Grow 11 Percent Annually, says PricewaterhouseCoopers 6Roche Diagnostics Opens State-of-the-Art Training Center in California 2ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 2ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 3ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 4ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 5ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 6ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 7Prime Retail Launches Operation Shop Pink 56749 1Prime Retail Launches Operation Shop Pink 56749 2WaferGen Closes on Private Financings of Approx 246 2 Million 13975 1WaferGen Closes on Private Financings of Approx 246 2 Million 13975 2WaferGen Closes on Private Financings of Approx 246 2 Million 13975 3ABRISA Appoints Jim Veler as President CEO 13971 1ABRISA Appoints Jim Veler as President CEO 13971 2ABRISA Appoints Jim Veler as President CEO 13971 3